Modeling studies like the one presented by Qiushi Chen and colleagues can project where needs and opportunities exist to address the pricing structure of medications and the selection of management strategies in CLL.
Related Article: Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States)
